FDA Aligns on Phase 3 Endpoint for CAD-1005 in HIT, Clearing Path to Registration
CVKD is trading near its 52-week low of $1.49 (9.4% above the low).
Summary
Cadrenal announced positive feedback from a July 28 FDA Type D meeting, with alignment on the primary endpoint and statistical analysis plan for the Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT). The FDA agreed to an optimized definition of worsening HIT based on progression of thrombotic events through Day 14 or hospital discharge, and to a placebo-controlled design with standard anticoagulation in both arms. This de-risks the pivotal trial design and clarifies the regulatory path for a drug targeting a ~50,000-patient annual U.S. market with a projected $2B peak revenue opportunity. The company has a going concern warning and cash runway only into October 2026, so this regulatory progress is critical for attracting financing or partnership. Next milestone is initiation of the Phase 3 trial, though no start date was provided.
At the time of this announcement, CVKD was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.49 to $14.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.